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Background: Real-world data on non-vitamin K oral anticoagulants (NOACs) are essential in determining whether
evidence from randomised controlled clinical trials translate into meaningful clinical benefits for patients in
everyday practice. RIVER (RIVaroxaban Evaluation in Real life setting) is an ongoing international, prospective registry
of patients with newly diagnosed non-valvular atrial fibrillation (NVAF) and at least one investigator-determined risk
factor for stroke who received rivaroxaban as an initial treatment for the prevention of thromboembolic stroke. The
aim of this paper is to describe the design of the RIVER registry and baseline characteristics of patients with newly
diagnosed NVAF who received rivaroxaban as an initial treatment.
Methods and results: Between January 2014 and June 2017, RIVER investigators recruited 5072 patients at 309
centres in 17 countries. The aim was to enroll consecutive patients at sites where rivaroxaban was already routinely
prescribed for stroke prevention. Each patient is being followed up prospectively for a minimum of 2-years. The
registry will capture data on the rate and nature of all thromboembolic events (stroke / systemic embolism),
bleeding complications, all-cause mortality and other major cardiovascular events as they occur. Data quality is
assured through a combination of remote electronic monitoring and onsite monitoring (including source data
verification in 10% of cases). Patients were mostly enrolled by cardiologists (n = 3776, 74.6%), by internal medicine
specialists 14.2% (n = 718) and by primary care/general practice physicians 8.2% (n = 417). The mean (SD) age of
the population was 69.5 (11.0) years, 44.3% were women. Mean (SD) CHADS2 score was 1.9 (1.2) and CHA2DS2-VASc
scores was 3.2 (1.6). Almost all patients (98.5%) were prescribed with once daily dose of rivaroxaban, most
commonly 20 mg (76.5%) and 15 mg (20.0%) as their initial treatment; 17.9% of patients received concomitant
antiplatelet therapy. Most patients enrolled in RIVER met the recommended threshold for AC therapy (86.6% for
2012 ESC Guidelines, and 79.8% of patients according to 2016 ESC Guidelines).
Conclusions: The RIVER prospective registry will expand our knowledge of how rivaroxaban is prescribed in
everyday practice and whether evidence from clinical trials can be translated to the broader cross-section of
patients in the real world.
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Atrial fibrillation (AF) is the most common sustained
arrhythmia reported in adult patients [1] and is associated
with an at least a five-fold increase in the risk of stroke [2].
Vitamin K antagonists (VKAs) formed the cornerstone of
thromboembolic prophylaxis in patients with AF for many
years. The introduction of non-vitamin K anticoagulants
(NOACs), dabigatran, rivaroxaban, apixaban and edoxaban,
provided physicians with agents with comparative efficacy
and reduced potential for bleeding compared with vitamin
K antagonists, while removing the need for dose titration,
periodic laboratory testing and dietary restrictions that are
necessary with VKAs [3–5]. Evidence from phase III studies
showed that rivaroxaban, one of several oral direct Factor
Xa inhibitors, is noninferior to warfarin for the reduction of
stroke or systemic embolism in patients with AF [6] and sig-
nificantly reduces rates of intracranial and fatal haemor-
rhages, but not rates of bleeding overall. Based on these
results, rivaroxaban is now licensed in more than 130 coun-
tries worldwide for stroke prevention in patients with AF.
Real-world studies (such as Global Anticoagulant Registry
in the FIELD-AF [GARFIELD-AF] [7], ORBIT-AF I & II) [8]
and GLORIA-AF [9, 10] have demonstrated that NOAC use
is increasing while post-marketing surveillance (such as Xar-
elto® for Prevention of Stroke in Patients with Atrial Fibrilla-
tion [XANTUS]) [11] and national studies (such as the
EXPAND) [12, 13] have provided data on the safety and effi-
cacy of rivaroxaban. However, most of these registries are
disease-specific and evaluate treatment patterns and out-
comes across different treatments. Therefore, additional
drug-specific observational studies are needed to assess the
clinical and health economic risk-benefits of specific
NOACs and in particular, the factors that could potentially
influence outcomes (e.g. compliance with prescribing guide-
lines, persistence and comorbidities) for each treatment al-
ternative separately. This paper describes the design of the
RIVaroxaban Evaluation in Real life setting (RIVER) registry
and baseline characteristics of patients who received rivarox-
aban as part of routine care. This paper also includes an ini-
tial analysis of the doses of rivaroxaban used in everyday
practice as well as a description of the use of rivaroxaban in
combination with antiplatelets in different clinical scenarios,
such as patients with renal impairment.Methods
Registry design
RIVER (NCT02444221) is an ongoing international,
multicentre, prospective registry of patients with newlydiagnosed non-valvular AF and at least one investigator-
determined risk factor for stroke. All patients in this study
are initiated on an anticoagulant treatment with rivaroxa-
ban at the start of the study, as part of routine care, for
the prevention of thromboembolic stroke.
The goal of the RIVER registry is to provide insights into
the clinical management and related outcomes of
rivaroxaban-treated AF patients across a number of regions
and across the spectrum of healthcare systems, in routine
clinical management. Follow-up will be for a minimum of
2 years (and up to 3.5 years) after enrolment (Fig. 1). By
capturing data from unselected patients treated in everyday
practice, the registry has the potential to identify best prac-
tices as well as deficiencies in the use of rivaroxaban as an
initial treatment for the prevention of thromboembolic
events in patients with newly diagnosed AF. The decision
to initiate treatment with rivaroxaban was based on clini-
cians’ judgement. The study was designed such that the col-
lection of data would not interfere with the clinical
management of patients or with the prescribing behaviours
of attending physicians. No specific treatments, tests, or
procedures were mandated or withheld from patients, and
patients were free to withdraw from the registry at any
time. The registry will not only assess the rates of clinical
outcomes such as stroke and systemic embolization (SE),
all-cause mortality, other major cardiovascular events
(Table 1) and bleeding complications, but will also evaluate
therapy persistence (including discontinuation, interruption
and changes to the treatment regimen). Patients’ experi-
ences using antithrombotic treatment will also be evaluated
by the Anti-Clot Treatment Scale (ACTS) questionnaire.
Independent ethics committee and hospital-based in-
stitutional review board approvals were obtained, as ne-
cessary, for the registry protocol. The registry is being
conducted in accordance with the Declaration of
Helsinki, local regulatory requirements, and the Inter-
national Conference on Harmonisation–Good Pharma-
coepidemiological and Clinical Practice guidelines.
RIVER is an independent academic research initiative,
sponsored by the Thrombosis Research Institute, London,
UK and funded by an unrestricted research grant from
Bayer AG, Berlin, Germany. The authors are responsible
for the design and conduct of this study, data analyses and
the final content of this paper.Registry population and site selection
The study population consists of consecutive patients
enrolled prospectively at sites where rivaroxaban was
Fig. 1 Cohort design and data collection
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the start of the study. Patients, receiving rivaroxaban as
part of usual care, were eligible for enrolment in RIVER
if they were 18 years of age or older, had a new diagnosis
of non-valvular AF within the past 6 weeks and at least
one additional risk factor for stroke as identified by the
investigator. These risk factors were identified by clini-
cians and were not restricted to those in stroke preven-
tion guidelines. Patients with a transient reversible cause
of AF, those for whom follow-up is not foreseen or possible
and all patients participating in interventional studies were
excluded. All patients provided written informed consent to
participate. Sites were chosen to be representative of AF care
settings and included patients from multiple settings:
office-based specialists, hospital departments (neurology, car-
diology, geriatrics, internal medicine, and emergency room),
anticoagulant clinics and general or family practice settings.
Data capture
Patient visits are not mandated, but data collection using
the electronic case report form (eCRF) occurs at
4-monthly intervals and captures all relevant data from
the patients’ medical notes (Fig. 1).
A summary of the evaluations performed at baseline
and at follow-up visits are outlined in Additional file 1:
Table S1. At entry into the study, data are collected on
the care setting, patients’ demographics, vital signs,
medical history, the nature of AF (paroxysmal versus
persistent versus permanent), symptoms of AF, relevant
medications, including antiplatelet and other concomi-
tant therapy and investigator-identified risk factors for
stroke. The results from investigations at diagnosis(including ECG morphology, left ventricular ejection
fraction [LVEF] measurement, full blood count, haemo-
globin, platelet count and creatinine) are recorded as
well as the treatment strategy for AF (rate or rhythm
control) and the date and outcome following cardiover-
sion. Information is collected on initial rivaroxaban dos-
ing regimen, start and stop dates, changes in therapy,
compliance concerns and the reason for suspending or
terminating therapy sooner than intended (such as
bleeding, patient decision, and/or physician decision).
Patients’ experiences using antithrombotic treatment are
recorded on the Anti-Clot Treatment Scale (ACTS)
questionnaire at 4, 12 and 24 months.
At 4-monthly intervals, all routinely performed tests (in-
cluding INR, haemoglobin, platelet count and creatinine),
vital signs as well as all major events (stroke/transient is-
chaemic attack [TIA], bleeding / site of bleeding, death,
myocardial infarction [MI], acute coronary syndrome
[ACS], peripheral embolism) and hospitalizations/medical
consultations are documented. For patients who switch to
VKAs, data are also collected on INR, INR frequency and
outcome related to INR fluctuation.
Based on the data collected from the eCRF, healthcare re-
source consumption will be captured so that the economic
burden of AF can be computed both overall and per patient
per year from the perspective of the payer, e.g. national
health service, public/private/statutory insurance etc.
Data management
Data are captured using an electronic case report form
(eCRF) designed by eClinicalHealth Services, Stirling,
UK and submitted electronically via a secure website to
Table 1 Main Outcome Measures in the RIVER Registry
Outcome Category
Clinical events Stroke (ischaemic and haemorrhagic)
Transient ischaemic attack
Peripheral/non-central nervous
system embolism
Pulmonary embolism
Heart failure
Myocardial infarction
Hospitalization
Sudden cardiac death
Non-cardiovascular death
Bleeding events
Severity Major
Non-major clinically relevant
Minor
Location Intracranial
Ears, nose, throat
Gastrointestinal
Genitourinary
Vascular access site
Outcome Recovered
Permanently disabled
Fatal
Healthcare utilization used for
bleeding event
Hospitalization
Emergency room visit
Surgery for bleeding
Transfusion
Physician consultation
Therapy persistence Rate of discontinuation
Duration of time on therapy
Reasons for discontinuation
Hospitalization for any event
Any other hospital visits Inpatient, outpatient, and
emergency room
Patients treated with
vitamin K antagonists
Frequency and timing of monitoring
INR recordings in relation
to therapeutic range
Location of testing (self-monitoring,
general practitioner clinic,
anticoagulant clinic, etc.)
Dose adjustments
Use of bridging anticoagulation
necessitated by interruption of
vitamin-K antagonist
Outcomes in relation to
INR fluctuation
Patients treated with additional
antithrombotic therapy
Therapy changes (discontinuation,
temporary interruptions and use
of bridging therapy)
Table 1 Main Outcome Measures in the RIVER Registry
(Continued)
Outcome Category
Reasons of therapy changes
(if applicable)
Patient treatment satisfaction using
the Anti-Clot Treatment Scale (ACTS),
depending on the cohort and
country (at 4, 12, 24 months)
INR International normalise ratio
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Research Institute who were responsible for checking
the completeness and accuracy of data collected from
medical records. All patients are assigned a unique
identifier and personal identifiable data will be re-
moved at the hospital source, ensuring anonymity and
protecting confidentiality.
Data quality is assured through a combination of remote
electronic monitoring and more conventional onsite moni-
toring (including source data verification in 10% of all cases),
based on the validated quality assurance programmes devel-
oped in GARFIELD-AF [14]. The milestones for study
eCRFs will be examined by the registry-coordinating centre
at TRI, to ascertain completeness, accuracy and data queries
sent to participating sites.
Statistical analysis
Continuous variables are expressed as mean ± standard
deviation (SD). Categorical variables are expressed as
frequencies and percentages. Statistical analysis was per-
formed using SAS software version 9.4 (SAS Institute
Inc., Cary, NC, USA).
Results
Baseline characteristics
A total of 5282 patients were screened for inclusion into
RIVER between January 2014 and June 2017 and 5072
eligible patients were included in the analysis of baseline
characteristics. Reasons for the exclusion of 210 patients
after screening were: age ≤ 18 years (n = 4), alternative
AC treatment before rivaroxaban after AF diagnosis
(n = 68), no risk factor for stroke (n = 22), patients hav-
ing transient AF secondary to a reversible cause (n = 10),
difficulty in long-term follow-up (n = 24), patients par-
ticipating in other interventional studies (n = 9) and, fi-
nally, patients whose enrolment was not confirmed due
to either patient’ decision (n = 27), death before consent
(n = 1) or other reason (n = 77). Patients were recruited
from 309 centres in 17 countries, including patients
from Europe (67.5%) (Denmark, France, Germany, Italy,
Netherlands, Poland, Russia, Spain, Sweden and UK),
the Middle East (17.0%) (Egypt, Saudi Arabia and UAE),
Australia (5.8%), Canada (3.0%), Brazil (5.6%) and
Mexico (1.1%) (Fig. 2). Overall, 74.6% (n = 3779) of
Fig. 2 Location of enrolling centres of the RIVER Registry. Australia, Brazil, Canada, Denmark, Egypt, France, Germany, Italy, Mexico, Netherlands,
Poland, Russia, Saudi Arabia, Spain, Sweden, UAE, UK
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by internal medicine specialists and 8.2% (n = 417) by
primary care/general practice physicians.
Approximately one-third of patients (36.3%) in RIVER
had asymptomatic AF. Among patients with symptom-
atic AF, the most common symptoms identified were:
palpitations (38.4%), shortness of breath (31.8%) and
tiredness (14.8%). At the time of enrolment, 34.2% of pa-
tients had new or unclassified AF, 34.2% paroxysmal AF,
15.9% persistent AF and 15.7% permanent AF.
Baseline patient characteristics are described in Table 2.
Caucasian patients represented the largest proportion of
patients in RIVER (80.3%), followed by Asians (5.6%)
and hispanic/latino (3.7%). Beyond the factors defined by
CHA2DS2-VASc, physicians also considered the follow-
ing as risk factors for stroke: smoking (12.8%), obesity
(19.5%), renal impairment (5.9%), proteinuria (1.9%), en-
larged left atrium (16.4%), thyroid disease (5.9%),
thrombus in atrium (0.4%) and Chagas disease (0.3%)
amongst others (5.3%).
Figure 3 describes the prescribing of rivaroxaban ac-
cording to the post-hoc calculation of CHADS2 and
CHA2DS2-VASc risk scores. The mean (SD) CHADS2
score for patients in the RIVER was 1.9 (1.2) and 58.2% of
patients had a score of ≥2. Mean (SD) CHA2DS2-VASc
score was 3.2 (1.6). Most patients met the recommended
threshold for AC therapy (86.6% for 2012 ESC Guidelines,
and 79.8% of patients according to 2016 ESC Guidelines).
The mean (SD) HAS-BLED score was 1.1 (0.8) and the
most commonly observed bleeding risk factors were:hypertension (77.0%), stroke (7.2%) and moderate-to-
severe chronic renal disease (4.6%).Rivaroxaban dosing
Almost all patients (98.5%) were prescribed a single daily
dose of rivaroxaban, most commonly 20mg (76.5%) and
15mg (20.0%), while10 mg dose was prescribed in only
2.1% of patients. Creatinine clearance (CrCl) information
at enrolment, estimated using the Cockcroft-Gault equa-
tion, was available for 3135 of 5072 (61.8%) patients.
The mean (SD) CrCl was 83.7 (35.6) mL/min and 86.1%
patients had CrCl ≥50mL/min. Among patients with
normal or mild renal function (CrCl ≥50mL/min), 2246
(83.2%) were prescribed the recommended rivaroxaban
dose of 20mg once daily at baseline. Of patients with mod-
erate or severe renal impairment (CrCl 15–49mL/min),
246 (56.6%) patients received rivaroxaban 15mg once daily,
173 (39.8%) 20mg once daily and 16 (3.7%) 10mg once
daily as their initial treatment.Concomitant antiplatelet therapy
Just under one in five (17.9%, n = 904) patients who were
initiated on rivaroxaban at the time of diagnosis of AF also
received concomitant antiplatelet therapy. Use of antipla-
telets was higher in patients with a CHA2DS2-VASc score
of 2–9 (19.4%) than in those with a score of 0 or 1 (9.2%)
(Table 3); 229 (25.3%) had a coronary artery disease
(CAD), peripheral artery disease (PAD) or carotid disease.
The most frequently used antiplatelet was aspirin in 55.4%
Table 2 Patient baseline characteristics
Variable All patients
(N = 5072)
Agea, mean ± SD, years 69.5 ± 11.0
Age groupa, n (%)
< 65 1444 (28.5)
65–74 1861 (36.8)
≥ 75 1758 (34.7)
Women, n (%) 2248 (44.3)
Body mass indexb, mean ± SD, kg/m2 29.2 ± 5.7
Smoking status (current/previous)c, n (%) 1599 (35.3)
Pulsed, mean ± SD, bpm 85.1 ± 23.8
Medical history, n (%)
Hypertensione 3899 (77.0)
Hypercholesterolemiaf 2208 (43.9)
Diabetes mellitusg 1227 (24.3)
Congestive heart failureh 1086 (21.5)
Family history of cardiac diseasei 618 (19.5)
Coronary artery diseasej 967 (19.2)
Current/History of myocardial infarction
or unstable anginak
718 (14.2)
Chronic renal diseasel
Mild renal dysfunction (stage: I, II) 629 (13.5)
Moderate renal dysfunction (stage: III) 186 (4.0)
Severe renal dysfunction (stage: IV, V) 26 (0.6)
Left ventricular ejection fraction < 40%m 305 (9.5)
Stroken 365 (7.2)
Transient ischaemic attacko 331 (6.5)
Aortic or peripheral artery diseasep 252 (5.0)
Carotid diseaseq 212 (4.2)
History of bleedingr 118 (2.3)
Heavy alcohol consumptions 83 (2.1)
Venous thromboembolismt 103 (2.0)
Systemic embolizationu 56 (1.1)
Cirrhosisv 20 (0.4)
aData not available for 9 patients
bData not available for 586 patients
cData not available for 541 patients
dData not available for 236 patients
eData not available for 9 patients
fData not available for 44 patients
gData not available for 12 patients
hData not available for 10 patients
iData not available for 1906 patients
jData not available for 28 patients
kData not available for 21 patients
lData not available for 395 patients
mData not available for 1870 patients
nData not available for 11 patients
oData not available for 15 patients
pData not available for 29 patients
qData not available for 53 patients
rData not available for 12 patients
sData not available for 1087 patients
tData not available for 15 patients
uData not available for 17 patients
vData not available for 24 patients
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dual AP therapy (ADP receptor/P2Y12 and aspirin).
Discussion
Observational or non-interventional studies play an im-
portant role in understanding and confirming the clin-
ical effectiveness of interventions across the spectrum
patients treated in routine practice.
RIVER is an independent treatment registry of patients
from multiple care settings and patients were recruited
from 17 countries. The RIVER registry provides an op-
portunity to examine the impact of different recruitment
methodologies on the characteristics and treatment be-
tween the registries. RIVER will document the regional
heterogeneity in the clinical presentation and assess the
rate of stroke and systemic embolism and other out-
comes with specific reference to the incidences of bleed-
ing and therapy persistence. In addition to reporting on
pre-specified clinical and economic outcomes, analyses
from RIVER will be hypothesis generating, allowing the
exploration of some aspects of the real world situation
of AF treated with rivaroxaban and outcomes.
The degree of the patient involvement in the gener-
ation of data is expected to provide unique insights into
the patients-reported outcomes. Patients’ experiences
using antithrombotic treatment are recorded on the
Anti-Clot Treatment Scale (ACTS) questionnaire. It is
important to recognise that registries differ in their de-
sign, recruitment strategies, care settings, geographical
spread and duration of follow-up. Compared to other
ongoing prospective registries, the RIVER registry has
the potential to capture the medicosocial burden due to
AF in large-scale populations by employing broad inclu-
sion and exclusion criteria in widely representative pop-
ulations of patients with AF who are treated with
rivaroxaban, across a range of clinical settings and to
capture long-term follow-up data. The value of RIVER
registry is enhanced by a quality assurance programme
and the supervision of an independent Audit Commit-
tee, which oversees site-dependent verification, remote
site monitoring and electronic database monitoring to
ensure data quality.
There are several phase IV studies (such as XANTUS
[15], XAPASS [16], XASSURE (China; NCT02784717)
and registries such as EXPAND [12]) are ongoing to in-
vestigate rivaroxaban in patients with NVAF in the real
world clinical settings. The XANTUS program com-
prises three studies: the XANTUS (Europe, Israel plus
enrollment in Canada; NCT01606995), XANTUS-EL
(Eastern Europe, Eastern Mediterranean, Middle East,
Latin America; NCT01800006) and XANAP (Asia-Paci-
fic; NCT01750788) [15].
Other ongoing non-interventional registries also pro-
vide real-world data on the effectiveness and safety of
Fig. 3 a Distribution of CHADS2 b CHA2DS2-VASc and c HAS-BLED scores in RIVER registry
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in the FIELD (GARFIELD)-AF [17], Outcomes Registry
for Better Informed Treatment of Atrial Fibrillation
(ORBIT)-AF I and ORBIT-AF II [18–21], the Global
Registry on Long-Term Oral Anthithrombotic Treat-
ment in pateints with Atrial Fribrillation (GLORIA-AF)
[22–26] and the Dresden NOAC Registry [4, 5, 27]
(Additional file 1: Table S2).
In the presence of all these observational studies, it is
important to highlight that there are a number of im-
portant differences in the design (Additional file 1: Table
S2) and recruitment of patients (Table 4) in RIVER com-
pared with these registries. RIVER is a drug-specific
registry which allows studying of drug utilisation pat-
terns including off-label use whereas other registries like
GARFIELD-AF, ORBIT-AF I and II, GLORIA-AF and
Dresden NOAC are disease-specific registries which al-
lows studying of burden, management and adverse event
profile for different treatments related to a specificTable 3 Use of antithrombotic drugs at diagnosis, overall and accor
Antiplatelet druga All patients (N = 5072)
Acetylsalicylic acid (Aspirin/ASA) 501 (9.9)
ADP receptor/P2Y12 inhibitor 248 (4.9)
Glycoprotein IIb/IIIa inhibitor 9 (0.2)
Prostaglandin analogue 71 (1.4)
Other antiplatelet 8 (0.2)
aCategories are not mutually exclusivedisease. Patients in XANTUS study were enrolled from
Europe, Israel and Canada whereas EXPAND and
XAPASS are Japanese registries and ORBIT-AF registries
are restricted to USA [19]. By contrast, RIVER has recruited
patients more broadly from 17 countries (outside Asia) in-
cluding Europe, the Middle East, Latin America, Canada and
Australia. RIVER provides long-term follow-up data of 2
years where as XANTUS had 1-year follow-up data. RIVER
is a more contemporary population in which physicians’ now
have experience using the NOACs. It is a known
phenomenon that, after approval of new treatments, physi-
cians start to apply these first in well-defined, carefully se-
lected populations and expand it to other populations only
after a period of time, which is reflecting learning curves
based on increased comfort levels, communication of real
world evidence, newly reported and previously unknown side
effects or changes in guideline recommendations [28–30] .
As a consequence, treatment patterns and outcomes may
shift over time, which is an additional justification for moreding to CHA2DS2-VASc scores of 0 or 1 and 2–9
Patients with CHA2DS2-VASc
score of 0 or 1 (N = 665)
Patients with CHA2DS2-VASc
score 2–9 (N = 4289)
28 (4.2) 465 (10.8)
13 (2.0) 231 (5.4)
2 (0.3) 6 (0.1)
5 (0.8) 66 (1.5)
2 (0.3) 6 (0.1)
Table 4 Comparison of adjusted demographic and baseline clinical characteristics of patients from the international observational
studies (RIVER and XANTUS), studies from Japan (EXPAND and XAPASS)
RIVER XANTUS EXPAND XAPASS
Patients, n 5072 6784 7141 11,308
Patient characteristics
Sex, male (%) 55.7 59.2 67.7 61.9
Age, mean (SD) 69.5 (11.0) 71.5 (10.0) 71.6 (9.4) 73.1 (9.9)
BMI (Kg/m2), mean (SD) 29.2 (5.7) 28.3 (5.0) NA 23.7 (3.8)
Creatinine clearance (mL/min), mean (SD) 83.7 (35.6) NA 69.7 (26.2) 67.7 (28.9)
< 15 mL/min (%) 0.02 0.3 NA 0.03
≥ 15 to < 30 mL/min (%) 0.7 1.1 1.9 2.8
≥ 30 to < 50 mL/min (%) 7.9 8.0 18.9 21.1
≥ 50mL/min (%) 53.4 56.2 74.6 68.0
Missing (%) 38.0 34.4 4.7 8.2
Rivaroxaban dose/dosing frequency
10mg once daily 105 (2.1) NA NA NA
15mg once daily 1008 (20.0) 1410 (20.8) NA NA
20mg once daily 3867 (76.5) 5336 (78.7) NA NA
10mg twice daily 10 (0.2) NA NA NA
15mg twice daily 29 (0.6) NA NA NA
20mg twice daily 22 (0.4) NA NA NA
10/15/20 mg other dosing Regimen 12 (0.2) 35 (0.5) NA NA
CHADS2 score, mean (SD) 1.9 (1.2) 2.0 (1.3) 2.1 (1.3) 2.2 (1.3)
CHA2DS2-VASc score, mean (SD) 3.2 (1.6) 3.4 (1.7) 3.4 (1.7) NA
Comorbidity/medical history
Congestive heart failure (%) 21.5 18.6 26.1 25.0
Hypertension (%) 77.0 74.7 70.9 74.3
Diabetes mellitus (%) 24.3 19.6 24.3 22.3
History of stroke/systemic embolism/TIA (%) 13.4 19.0 24.1 23.7
Type of AF
Paroxysmal (%) 34.2 40.7 44.8 NA
Non-paroxysmal (persistent/permanent) (%) 31.6 40.8 55.2 NA
First diagnosed (%) 34.2 18.5 NA NA
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have contributed to the observed differences in patients char-
acteristics, compared to other observational studies. Patients
in RIVER are younger (mean age: 69.5 years) than patients in
EXPAND (72 yrs), XANTUS (71.5 yrs), and XAPASS (73.1
yrs). The mean BMI of patients in RIVER (29.2 ± 5.7) is
higher than the Japanese cohort in XAPASS (23.7 ± 3.8)
(Table 4). Patients studied in RIVER also had a lower risk of
stroke, with a mean CHADS2 scores of 1.9 and 13.4% had a
prior episode of stroke/TIA/SE when compared to XANTUS
(2.0, 19%) and XAPASS (2.2; 23.7%) (Additional file 1: Table
S3) and other NOAC trials, such as RE-LY (2.1; 20.0%) and
ARISTOTLE (2.1; 19.4%) [31, 32]. Nevertheless, patients in
RIVER had high rates of comorbid conditions, including
hypertension, hypercholesterolemia, diabetes mellitus, heartfailure and coronary artery disease. However, the proportion
of patients (8.6%) with renal dysfunction (CrCl < 50mL/min)
in RIVER was similar to XANTUS (9.4%) and lower than
Japanese cohorts in EXPAND (20.8%) and XAPASS (23.9%);
although this observation may be due to the higher rates of
missing CrCl measurements in both RIVER (38.0%) and
XANTUS (34.4%). Patients in RIVER and XANTUS received
higher doses of rivaroxaban (20mg/day [76.5 and 78.7% pa-
tients, respectively], 15mg/day [20.0 and 20.8% patients, re-
spectively]) than those in EXPAND (15mg/day [56.6%
patients], 10mg/day [43.4% patients]), suggesting differences
in the guideline recommendations, which are based on pa-
tient characteristics and ethnicities. In Japan, the regular dos-
age of rivaroxaban is 15mg od, which is lower than the
global recommended dosage of 20mg od [33].
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Centres for recruitment of patients in RIVER are limited to
the care settings where rivaroxaban is the standard of care
and includes sites beyond those included in the clinical tri-
als. Comparison of different treatments are not possible, as
there is no comparator drug, while larger prospective disease
registries such as GARFIELD-AF and drug registries such as
GLORIA-AF and ORBIT-II have the potential to conduct
comparative effectiveness studies between different treat-
ment approaches in newly diagnosed patients with AF. Due
to the observational design of the study, laboratory and
other investigations could not mandated.
Strengths
RIVER is an independent academic research initiative. This
prospective registry was designed with a novel approach to
outcomes research, including the following features: sites
representation of national AF care settings, randomised site
selection, unselected eligible patients enrolled consecutively
with a follow-up period of minimum 2 years and extensive
monitoring and audit including source data verification of
10% of all eCRFs. Like other prospective registries, such as
GARFIELD-AF [34], RIVER aims to overcome the inherent
bias of retrospective cohort studies from national registries
and claims databases [35–39].
Conclusion
The RIVER prospective registry will expand our knowledge
of how rivaroxaban is prescribed in everyday practice and
whether evidence from clinical trials can be translated to the
broader cross-section of patients treated in the real world.
Additional file
Additional file 1: Table S1. Evaluations performed at Baseline and at
Follow-Up Visits. Table S2. Study design of ongoing real-world studies of
rivaroxaban. Table S3. Comparison of distribution of baseline CHADS2,
CHA2DS2-VASc or HAS-BLED scores of patients from observational RIVER,
XANTUS, EXPAND and XAPASS studies. (DOC 155 kb)
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